HCM Valuation

HUTCHMED (China) Ltd

Add to Watchlist

Advanced Chart

14.380

-0.870(-5.700%)

Overview
Forecast
Valuation

HCM Relative Valuation

HCM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HCM is overvalued; if below, it's undervalued.

Historical Valuation

HUTCHMED (China) Ltd(HCM) is now in theUndervaluedzone, suggesting that its currentforward PSratio of3.49is consideredUndervaluedcompared with the five-year average of5.85.The fair price of HUTCHMED (China) Ltd(HCM)is between17.97to45.76according to relative valuation methord.Compared to the current price of14.38USD, HUTCHMED (China) Ltd isUndervalued By 19.98%.

Relative Value

Fair Zone

17.97-45.76

Current Price：14.38

19.98%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

16.18

P/B

Median3y

5.79

Median5y

5.78

-0.70

FCF Yield

Median3y

-4.20

Median5y

-4.03

Competitors Valuation Multiple

The average P/S ratio for HCM's competitors is 13.27, providing a benchmark for relative valuation. HUTCHMED (China) Ltd Corp (HCM) exhibits a P/S ratio of 3.49, which is -73.72% above the industry average. Given its robust revenue growth of %, this premium appearsunsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap